¼¼°èÀÇ ¸Ö¹Ì¾à ½ÃÀå
Motion Sickness Drugs
»óǰÄÚµå : 1794489
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 270 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,209,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,629,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¸Ö¹Ì¾à ½ÃÀåÀº 2030³â±îÁö 7¾ï 2,140¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 5¾ï 9,200¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¸Ö¹Ì¾à ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 3.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 7¾ï 2,140¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Ç×È÷½ºÅ¸¹ÎÁ¦´Â CAGR 4.1%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4¾ï 9,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç×Äݸ°Á¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 6,130¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸Ö¹Ì¾à½ÃÀåÀº 2024³â¿¡ 1¾ï 6,130¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 4,430¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.4%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.3%¿Í 2.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¸Ö¹Ì¾à½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸Ö¹Ì¾àÀÌ ¿©Çà°ú ÀÇ·á ÇöÀå¿¡¼­ ³Î¸® »ç¿ëµÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¸Ö¹Ì¾àÀº ¿©Çà ÁßÀ̳ª ½Ã¹Ä·¹ÀÌ¼Ç Áß À̵¿À¸·Î ÀÎÇÑ ¾îÁö·¯¿ò, ¸Þ½º²¨¿ò, ±¸Åä, ½ÄÀº¶¡ µîÀÇ Áõ»óÀ» ¿¹¹æÇÏ°í °ü¸®Çϱâ À§ÇØ »ç¿ëµË´Ï´Ù. ÀÌ ¾à¹°µéÀº ÁßÃ߽Űæ°è¿¡ ÀÛ¿ëÇÏ¿© ³»ÀÌÀÇ ½ÅÈ£¸¦ Â÷´ÜÇϰųª ÆòÇü°¨°¢°ú °ü·ÃµÈ °æ·ÎÀÇ °úµµÇÑ ÀÚ±ØÀ» ¾ïÁ¦ÇÔÀ¸·Î½á È¿°ú¸¦ ¹ßÈÖÇÕ´Ï´Ù. ÀÌ ¾àÁ¦µéÀº Ç×°ø, ÇØ»ó, À°·Î À̵¿»Ó¸¸ ¾Æ´Ï¶ó ¼ö¼ú ÈÄ °ü¸® ¹× ÀüÁ¤ Àå¾Ö¿¡µµ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ¸Ö¹Ì´Â ¹Ýº¹ÀûÀ̰ųª ¿¹±âÄ¡ ¾ÊÀº ¿òÁ÷ÀÓÀÌ Àִ Ȱµ¿ Áß¿¡ °¡Àå ºó¹øÇÏ°Ô ¹ß»ýÇϹǷΠ¿òÁ÷ÀÓ¿¡ ¹Î°¨ÇÏ°Ô ¹ÝÀÀÇÏ´Â »ç¶÷¿¡°Ô´Â ¾à¸®ÇÐÀû °³ÀÔÀÌ Áß¿äÇÕ´Ï´Ù.

¸Ö¹Ì¾àÀº ÀϹÝÀǾàǰ°ú 󹿾àÀÌ ÀÖÀ¸¸ç, °æ±¸¿ë Á¤Á¦, °æÇÇ Èí¼ö ÆÐÄ¡, Ãò¾îºí Á¤Á¦, ¾×Á¦ µîÀÌ ÀÖ½À´Ï´Ù. ³Î¸® »ç¿ëµÇ´Â ¾àÁ¦ À¯Çüº°·Î´Â ¸ÞŬ¸®µò, µð¸àÈ÷µå¸®³ªÆ® µîÀÇ Ç×È÷½ºÅ¸¹ÎÁ¦, ½ºÄÚÆú¶ó¹Î µîÀÇ Ç×Äݸ°Á¦, ÇÁ·Î¸ÞŸµò µîÀÇ µµÆÄ¹Î ±æÇ×Á¦ µîÀÌ ÀÖ½À´Ï´Ù. Ä¡·á ¹æ¹ýÀÇ ¼±ÅÃÀº ¿©Çà ±â°£, Áõ»óÀÇ ½É°¢¼º, »ç¿ëÀÚÀÇ ³»¼º¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ÀÌ ¾àÁ¦µéÀº Ä¡·á È¿°ú»Ó¸¸ ¾Æ´Ï¶ó ¿¹¹æ È¿°úµµ ÀÖÀ¸¸ç, ÀÏ»óÀûÀÎ »ç¿ë°ú ÀϽÃÀûÀÎ °ü¸®¿¡µµ ÀûÇÕÇÕ´Ï´Ù.

ÆíÀǼº°ú ³»¾à¼ºÀ» Çâ»ó½Ã۱â À§ÇØ Á¦Á¦´Â ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

Á¦Á¶¾÷üµéÀº ´õ ±ä ¿ÏÈ­ È¿°ú, »ç¿ë ÆíÀǼº, ÀûÀº ºÎÀÛ¿ëÀ» Á¦°øÇÏ´Â ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¸çÄ¥ µ¿¾È Áö¼ÓÀûÀ¸·Î ¹æÃâµÇ´Â °æÇÇ ÆÐÄ¡´Â Àå½Ã°£ÀÇ ¼±¹Ú ¿©ÇàÀ̳ª ºñÇà±â ¿©Çà¿¡ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ¾ÃÀ» ¼ö ÀÖ´Â Á¤Á¦³ª ±¸°­ºØÇØÁ¤Á¦´Â ¼Ò¾Æ³ª »ïŰ±â ¾î·Á¿î ȯÀÚ¿¡°Ô Æí¸®ÇÏ°Ô Åõ¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÁøÁ¤ ÀÛ¿ëÀÌ ÀûÀº Á¦Á¦´Â ƯÈ÷ ¿©Çà Áß ÁÖÀÇ·ÂÀ» À¯ÁöÇϰíÀÚ ÇÏ´Â ¿©Çà°´µé¿¡°Ô Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.

»õ·Î¿î Á¦Ç°Àº 1¼¼´ë Ç×È÷½ºÅ¸¹ÎÁ¦³ª Ç×Äݸ°Á¦¿¡¼­ ÈçÈ÷ ³ªÅ¸³ª´Â ±¸°­°ÇÁ¶Áõ, Á¹À½, ´«ºÎ½É µîÀÇ ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀüÁ¤ Áõ»ó°ú À§Àå Áõ»ó ¸ðµÎ¿¡ ´ëÀÀÇÏ´Â º´¿ë¿ä¹ýµµ °³¹ß ÁßÀÔ´Ï´Ù. ¶ÇÇÑ °¡»óÇö½Ç(VR) üÇè°ú °°Àº ¿òÁ÷ÀÓ ±â¹Ý ¿£ÅÍÅ×ÀÎ¸ÕÆ® Ç÷§ÆûÀÇ ¼ºÀåÀ¸·Î ÀÎÇØ ¿òÁ÷ÀÓÀ¸·Î ÀÎÇÑ ºÒÆíÇÔÀ» ÁÙÀ̸鼭 °¨°¢ÀÇ ¼±¸íµµ¸¦ À¯ÁöÇÏ´Â ºñÁøÁ¤¼º ¼ÓÈ¿¼º Á¦Á¦¿¡ ´ëÇÑ »õ·Î¿î ¼ö¿ä ¿µ¿ªÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù.

Áö¿ªº° ½ÃÀå ¼ö¿ä¸¦ Çü¼ºÇÏ´Â ÃÖÁ¾»ç¿ëÀÚ µ¿ÇâÀº?

¸Ö¹Ì¾àÀÇ »ç¿ëÀº ƯÈ÷ ¿©ÇàÀÌ ÀæÀº »ç¶÷, Å©·çÁî ½Â°´, Ç×°ø °ü°èÀÚµé »çÀÌ¿¡¼­ ¸¹ÀÌ »ç¿ëµË´Ï´Ù. ÇØ¿Ü¿©ÇàÀÌ Àç°³µÇ¸é¼­ °øÇ×, ¾à±¹, ¿©Çà Ŭ¸®´Ð¿¡¼­ À̵é ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ȸº¹µÇ°í ÀÖ½À´Ï´Ù. ¸Ö¹Ì¿¡ Ãë¾àÇÑ ¾î¸°ÀÌ¿Í ³ë³âÃþÀº º¸´Ù ¼øÇÏ°í ³»¾à¼ºÀÌ ³ôÀº Á¦Á¦¸¦ ã´Â Áß¿äÇÑ ¼ÒºñÀÚÃþÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á°è¿¡¼­´Â ¸Ö¹Ì¾àÀÌ ÀüÁ¤ ÆíµÎÅë°ú ³»ÀÌ Àå¾ÖÀÇ Ä¡·á º¸Á¶Á¦·Îµµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

·¹Àú º¸Æ®, ¾ß¿Ü °ü±¤, ³îÀ̰ø¿ø µî¿¡¼­µµ ¸Ö¹Ì¾àÀ» º¹¿ëÇÏ´Â °ÍÀÌ ÀϹÝÀûÀ¸·Î ±ÇÀåµÇ°í ÀÖ½À´Ï´Ù. ±º ¹× ±¹¹æ ºÐ¾ß¿¡¼­´Â ºñÇà ½Â¹«¿ø°ú ÇØ±º ¿ä¿øÀÇ ¿îµ¿ À¯¹ß¼º ¸Þ½º²¨¿òÀ» °ü¸®ÇÏ´Â °ÍÀÌ ¹Ì¼Ç Å©¸®Æ¼ÄÃÇÑ °ÍÀ¸·Î °£ÁֵǾî Àå½Ã°£ ÀÛ¿ëÇÏ°í ¼º´ÉÀ» À¯ÁöÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀ» »ç¿ëÇϵµ·Ï ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃÖÁ¾»ç¿ëÀÚÀÇ ´Ù¾çÇÑ È¯°æÀº Àü ¼¼°è¿¡¼­ Á¦Çü °³¹ß, ¿ë¹ý ¼±È£µµ, À¯Åë Àü·«¿¡ Áö¼ÓÀûÀ¸·Î ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¸Ö¹Ì¾à ¼Òºñ¿Í ±â¼ú Çõ½ÅÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

¸Ö¹Ì¾à ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ¿©Çà Áõ°¡, ¼ÒºñÀÚ ÀÎ½Ä Çâ»ó, Á¦Ç° µðÀÚÀÎ ÁøÈ­¿Í °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. Å©·çÁî ¹× ¸ðÇè ¿©Çà »ê¾÷ÀÇ È®´ë·Î ÀÎÇØ ¿òÁ÷ÀÓÀÌ ¸¹Àº ȯ°æ¿¡¼­ÀÇ ¿¹¹æ¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀüÁ¤Àå¾Ö Áø´Ü °Ç¼ö Áõ°¡¿Í Ä¡·á Á¢±Ù¼º Çâ»óÀ¸·Î 󹿾àÀÇ º¸±Þ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °æÇÇ Èí¼öÇü Á¦Çü°ú »ç¿ëÇϱ⠽¬¿î °æ±¸¿ë Á¦ÇüÀÇ Çõ½ÅÀ¸·Î ´Ù¾çÇÑ °èÃþÀÌ À̵é Á¦Ç°À» ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¸Ö¹Ì¾àÀº ÀüÀÚ ¾à±¹, Á¶Á¦ ¾à±¹ µî ´Ù¾çÇÑ ¼Ò¸Å ä³Î¿¡¼­ ±¸ÇÒ ¼ö ÀÖÀ¸¸ç, Á¦Ç°ÀÇ ÀÎÁöµµ¿Í ÆíÀǼºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñÇà ½Ã¹Ä·¹ÀÌÅͳª VR ¿ëµµ°ú °°ÀÌ ¿òÁ÷ÀÓÀÌ ¸¹Àº µðÁöÅРȯ°æÀ» Á¢ÇÒ ±âȸ°¡ ¸¹¾ÆÁö¸é¼­ ÁøÁ¤ ÀÛ¿ëÀÌ ¾ø°í È¿°ú°¡ ºü¸¥ ¸Ö¹Ì¾àÀÇ »õ·Î¿î ÀÌ¿ë »ç·Ê°¡ »ý°Ü³ª¸é¼­ ¼±Áø±¹°ú ½ÅÈï ½ÃÀåÀÇ ²ÙÁØÇÑ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¾àÁ¦ Ŭ·¡½ºº°(Ç×È÷½ºÅ¸¹ÎÁ¦, Ç×Äݸ°Á¦); À¯Åë ä³Îº°(¿ÀÇÁ¶óÀÎ À¯Åë ä³Î, ¿Â¶óÀÎ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Motion Sickness Drugs Market to Reach US$721.4 Million by 2030

The global market for Motion Sickness Drugs estimated at US$592.0 Million in the year 2024, is expected to reach US$721.4 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Antihistamines, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$490.1 Million by the end of the analysis period. Growth in the Anticholinergics segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$161.3 Million While China is Forecast to Grow at 6.4% CAGR

The Motion Sickness Drugs market in the U.S. is estimated at US$161.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$144.3 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Motion Sickness Drugs Market - Key Trends & Drivers Summarized

Why Are Motion Sickness Drugs Widely Used in Travel and Medical Settings?

Motion sickness drugs are used to prevent and manage symptoms such as dizziness, nausea, vomiting, and cold sweats caused by movement during travel or simulation. These drugs work by acting on the central nervous system to block signals from the inner ear or reduce overstimulation of the balance-related pathways. They are commonly used for air, sea, and land travel as well as in post-operative care and vestibular disorders. Motion sickness is most frequently experienced during activities involving repetitive or unanticipated motion, making pharmacological intervention important for individuals with high sensitivity to movement.

These drugs are available in both over-the-counter and prescription forms, in oral tablets, transdermal patches, chewable tablets, and liquid formulations. Widely used drug classes include antihistamines such as meclizine and dimenhydrinate, anticholinergics such as scopolamine, and dopamine antagonists like promethazine. The choice of therapy depends on duration of travel, severity of symptoms, and user tolerance. These medications provide preventive as well as therapeutic relief, making them suitable for routine use and episodic management alike.

How Are Drug Formulations Evolving to Improve Convenience and Tolerability?

Manufacturers are increasingly focusing on drug delivery systems that offer extended relief, ease of use, and fewer side effects. Transdermal patches, which provide continuous release over several days, are preferred for long-duration sea or air travel. Chewable and orally disintegrating tablets offer convenient administration for children or patients with swallowing difficulties. Formulations with reduced sedative effects are gaining popularity, especially for travelers who wish to remain alert during trips.

Newer products aim to minimize dry mouth, drowsiness, and blurred vision-side effects commonly associated with first-generation antihistamines and anticholinergics. Combination therapies that address both vestibular and gastrointestinal symptoms are also under development. Additionally, the growth of motion-based entertainment platforms such as virtual reality (VR) experiences has opened a new area of demand for non-sedating, rapid-acting formulations that maintain sensory clarity while reducing motion-induced discomfort.

What End-User Trends Are Shaping Market Demand Across Regions?

Use of motion sickness drugs is particularly high among frequent travelers, cruise passengers, and aviation personnel. With the resumption of international travel, demand for these medications is rebounding across airports, pharmacies, and travel clinics. Pediatric and geriatric populations, who are often more susceptible to motion sickness, form a significant consumer base for milder, well-tolerated formulations. In healthcare settings, motion sickness medications are also used as adjuncts in treating vestibular migraines and inner ear disorders.

The leisure boating sector, outdoor adventure tourism, and ride-based amusement parks represent additional market niches where such drugs are commonly recommended. In military and defense applications, managing motion-induced nausea in flight crews and naval personnel is considered mission-critical, prompting the use of long-acting and performance-preserving options. These diverse end-user settings continue to influence formulation development, dosage preferences, and distribution strategies globally.

What Is Driving Growth in Motion Sickness Drug Consumption and Innovation?

Growth in the motion sickness drugs market is driven by several factors related to increased global travel, higher consumer awareness, and evolving product design. Expansion of the cruise and adventure tourism industry is raising demand for preventive medications in high-motion environments. Rising diagnosis of vestibular disorders and better access to treatment are contributing to prescription drug uptake. Innovation in transdermal delivery systems and user-friendly oral formats is making these products more accessible to varied demographics. The availability of motion sickness drugs through multiple retail channels, including e-pharmacies and in-transit dispensaries, is enhancing product visibility and convenience. Additionally, increased exposure to motion-heavy digital environments such as flight simulators and VR applications is creating new use cases for non-sedating, fast-acting motion sickness drugs, supporting steady growth across developed and emerging markets.

SCOPE OF STUDY:

The report analyzes the Motion Sickness Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antihistamines, Anticholinergics); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â